A late-stage clinical trial revealed that a Chinese obesity drug, ecnoglutide, achieved significant weight loss results of over 15% after 48 weeks. This finding positions it as a prospective challenger to established blockbusters from Novo Nordisk and Eli Lilly, with comparable efficacy seen in previous studies for Lilly’s Zepbound. According to Hai Pan, CEO of Hangzhou Sciwind Biosciences Co., the promising results demonstrate ecnoglutide’s potential to revolutionize weight loss treatments in the market.
Source: https://www.bloomberg.com/news/articles/2025-06-21/chinese-biotech-showcases-challenger-to-eli-lilly-s-obesity-drug